This company listing is no longer active
Calliditas Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Calliditas Therapeutics has a total shareholder equity of SEK106.8M and total debt of SEK982.5M, which brings its debt-to-equity ratio to 920%. Its total assets and total liabilities are SEK1.7B and SEK1.6B respectively.
Key information
920.0%
Debt to equity ratio
SEK 982.49m
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 797.28m |
| Equity | SEK 106.79m |
| Total liabilities | SEK 1.64b |
| Total assets | SEK 1.75b |
Recent financial health updates
No updates
Recent updates
No updates
Financial Position Analysis
Short Term Liabilities: LC8A's short term assets (SEK1.2B) exceed its short term liabilities (SEK429.8M).
Long Term Liabilities: LC8A's short term assets (SEK1.2B) do not cover its long term liabilities (SEK1.2B).
Debt to Equity History and Analysis
Debt Level: LC8A's net debt to equity ratio (173.4%) is considered high.
Reducing Debt: LC8A's debt to equity ratio has increased from 0% to 920% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LC8A has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if LC8A has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.